Product Description
Overall, the global on-pump coronary artery bypass device market was valued at $550 million in 2023. This is expected to increase over the forecast period at a CAGR of 3% to reach $680 million. The global off-pump coronary artery bypass device market was valued at $230 million in 2023. This is expected to decrease at a CAGR of –0.7% to $220 million over the forecast period.
LivaNova, Terumo, and Medtronic were the share leaders in the global on-pump coronary artery bypass device market. This global analysis covers over 70 countries and includes ONCAB procedures and is segmented by the ONCAB disposables market and the perfusion system market.
Medtronic, Getinge, and Terumo were the share leaders within the global off-pump coronary artery bypass device market. This global analysis covers over 70 countries and includes OPCAB procedures and is segmented by the stabilizer device market and the positioner device market.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- ONCAB and OPCAB Procedures
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2030, and Historical Data to 2020
- Recent Mergers & Acquisitions
- Disease Overviews
- Company Profiles, Product Portfolios, and SWOT for Top Competitors
On-Pump Coronary Artery Bypass Device Market Insights
Globally, the use of coronary artery bypass grafting (CABG) has seen a decline, giving way to the less invasive transcatheter aortic valve replacement (TAVR) procedures. TAVR’s minimal recovery time has bolstered its appeal, potentially curtailing the market for on-pump CABG during the forecast period. While the number of procedures might be dropping, the CABG market is still poised for growth due to rising prices. Even with TAVR offering comparable clinical outcomes for certain patient groups, many physicians remain inclined towards the traditional ONCAB procedure.
Off-Pump Coronary Artery Bypass Device Market Insights
Although there has been a decrease in the number of procedures, rising prices are expected to fuel market growth over the forecast period. Given that the clinical outcomes of OPCAB are comparable to TAVR for certain patient risk profiles, many physicians prefer opting for OPCAB. Globally, the use of anastomosis assist devices is increasingly becoming popular, leading to shorter procedure times and fewer reported complications.
MARKET SHARE INSIGHTS
In 2023, LivaNova led the global ONCAB market, dominating the perfusion systems and disposables segments, with plans to increase its market share further. Terumo, ranking second, features products like Prestige Pack™ and the CAPIOX® and Sarns™ lines, expected to sustain its market position despite emerging regional competitors. Medtronic, third, offers products including tubing sets and biocompatible heparin-coated oxygenators like Cortiva® and Trillium®. Exiting the ventricular assist device market, Medtronic is poised to grow in the THVR segment.
Medtronic leads the OPCAB market, offering stabilizers like Octopus™ Evolution and heart positioners such as Starfish™ Evo. With its exit from ventricular assist devices, expansion in OPCAB is anticipated. Getinge, ranking second, with diverse cardiac products, faces potential market share decline due to a shrinking OPCAB market. Terumo, third in line, features innovative devices like the Universal Stabilizer Arm™, positioning it for growth in the market.
MARKET SEGMENTATION SUMMARY
On-Pump Coronary Artery Bypass Device Segments:
- ONCAB Disposables
- Perfusion System
Off-Pump Coronary Artery Bypass Device Segments:
- Stabilizer Devices
- Positioners
RESEARCH SCOPE SUMMARY
| Report Attribute | Details |
|---|---|
| Regions | North America(Canada, United States) Latin America(Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe(Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe(Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East(Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific(Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Mongolia, Malaysia, Myanmar, New Zealand, Philippines, Pakistan, Singapore, South Korea, Taiwan, Thailand, Uzbekistan, Vietnam) Africa(Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2023 |
| Forecast | 2024-2030 |
| Historical Data | 2020-2023 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
